Skip to main content

Agora
Sign in

House bill · H.R. 1672 (119th Congress)

Maintaining Investments in New Innovation Act

U.S. House of Representatives

Latest action Jun 18, 2026

Sponsor: Donald G. Davis (U.S. Representative, NC-1, Democratic)

Follow

Following needs an Agora account. You will sign in first, then come back to this page.

From Congress.gov and official rosters. This record was last updated Jul 30, 2026. About our data

Summary

Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Summary from the Congressional Research Service. How we handle summaries

Where it stands

Assigned to a committee for review.

  1. Introduced
  2. In committee
  3. Up for a vote
  4. Passed one chamber
  5. Passed
  6. Enacted

Committee

House Committee on Energy and Commerce · U.S. House of Representatives

Also referred to House Committee on Ways and Means · U.S. House of Representatives.

Your position on this bill

Choose the position closest to yours. You'll sign in or create an account to save it.

Sign in or create an account to give your position

Cosponsors

46

Cosponsors listed on Congress.gov, shown A to Z.

  • Republican41
  • Democratic5

This bill has cosponsors from more than one party.

Shown in neutral colors by design; Agora is non-partisan.

Show the full list (46 names)

Full history

  1. Jun 18, 2026

    Introduced

    Introduced in U.S. House

    U.S. House

  2. Feb 27, 2025

    Introduced

    Introduced in House

    U.S. House of Representatives

  3. Feb 27, 2025

    In committee

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    U.S. House

  4. Feb 27, 2025

    Referred to committee

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  5. Feb 27, 2025

    Referred to committee

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Show full history (1 earlier event)
  1. Feb 27, 2025

    Referred to committee

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Read the record